Autoantibody titers against OxLDL are correlated with Achilles tendon thickness in patients with familial hypercholesterolemia

Journal of Lipid Research

Volumn 47, Issue 10, 2006, Pages 2208-2214

  Tsouli, Sofia G ^a   Kiortsis, Dimitrios N ^a   Lourida, Evangelia S ^b   Xydis, Vasilios ^a   Tsironis, Loukas D ^b   Argyropoulou, Maria I ^a   Elisaf, Moses ^a   Tselepis, Alexandros D ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Antibody; Oxidized low density lipoprotein; Phospholipase A2; Platelet activating factor acetylhydrolase

Indexed keywords

IMMUNOGLOBULIN G; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2;

ACHILLES TENDON; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOGRAPHY; ENZYME ACTIVITY; ENZYME INACTIVATION; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOSITY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; OXIDATION; PRIORITY JOURNAL; XANTHOMA;

ACHILLES TENDON; ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LIPOPROTEINS, LDL; MIDDLE AGED; PHOSPHOLIPASES A;

EID: 33845597078     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M600109-JLR200     Document Type: Article

References (34)

1. Steinberg, D., S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
2. Bhakdi, S., K. J. Lackner, S. R. Han, M. Torzewski, and M. Husmann. 2004. Beyond cholesterol: the enigma of atherosclerosis revisited. Thromb. Haemost. 91: 639-645.
3. Holvoet, P., and D. Collen. 1998. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis. 137 (Suppl.): 33-38.
4. Esterbauer, H., J. Gebicki, H. Puhl, and G. Jurgens. 1992. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic. Biol. Med. 13: 341-390.
5. Tselepis, A. D., and M. J. Chapman. 2002. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler. Suppl. 3: 57-68.
6. Wu, R., Y. H. Huang, L. S. Elinder, and J. Frostegard. 1998. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 18: 626-630.
7. Palinski, W., and J. L. Witztum. 2000. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J. Intern. Med. 247: 371-380.
8. Shoenfeld, Y., R. Wu, L. D. Dearing, and E. Matsuura. 2004. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation. 110: 2552-2558.
9. Karabina, S-A. P., M. Elisaf, E. Bairaktari, C. Tzallas, K. C. Siamopoulos, and A. D. Tselepis. 1997. Increased activity of PAF-acetylhydrolase in low density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolemia. Eur. J. Clin. Invest. 27: 595-602.
10. Lourida, E. S., A. I. Papathanasiou, J. A. Goudevenos, and A. D. Tselepis. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease. Prostaglandins Leukot. Essent. Fatty Acids. Epub ahead of print. May 30, 2006; doi:10.1016/j.plefa.2006.03.012.
11. Bertolini, S., A. Cantafora, M. Averna, C. Cortese, C. Motti, S. Martini, G. Pes, A. Postiglione, C. Stefanutti, I. Blotta, et al. 2000. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler. Thromb. Vasc. Biol. 20: 41-52.
12. Mabuchi, H., R. Tatami, T. Haba, K. Ueda, R. Ueda, S. Ito, T. Karnetani, J. Koizurni, S. Miyamoto, M. Ohta, et al. 1978. Achilles tendon thickness and ischemic heart disease in familial hypercholesterolemia. Metabolism. 27: 1672-1679.
13. Tsouli, S. G., D. N. Kiortsis, M. I. Argyropoulou, D. P. Mikhailidis, and M. S. Elisaf. 2005. Pathogenesis, detection and treatment of Achilles tendon xanthomas. Eur. J. Clin. Invest. 35: 236-244.
14. Civeira, F., S. Castillo, R. Alonso, E. Merino-Ibarra, A. Cenarro, M. Artied, P. Martin-Fuentes, E. Ros, M. Pocovi, and P. Mata; Spanish Familial Hypercholesterolemia Group. 2005. Tendon xanthomas in familial hypercholesterolemia are associated with cardiovascular risk independently of the low-density lipoprotein receptor gene mutation. Arterioscler. Thromb. Vasc. Biol. 25: 1960-1965.
15. Kruth, H. S. 1985. Lipid deposition in human tendon xanthoma. Am. J. Pathol. 121: 311-315.
16. Tall, A. R., D. M. Small, and R. S. Lees. 1978. Interaction of collagen with the lipids of tendon xanthomata. J. Clin. Invest. 62: 836-846.
17. Artieda, M., A. Cenarro, C. Junquera, P. Lasierra, M. J. Martinez-Lorenzo, M. Pocovi, and F. Civeira. 2005. Tendon xanthomas in familial hypercholesterolemia are associated with a differential inflammatory response of macrophages to oxidized LDL. FEBS Lett. 579: 4503-4512.
18. Matsuura, E., K. Kobayashi, M. Tabuchi, and L. R. Lopez. 2006. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog. Lipid Res. In press.
19. Williams, R. R., S. C. Hunt, M. C. Schumacher, R. A. Hegele, M. F. Leppert, E. H. Ludwig, and P. N. Hopkins. 1993. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72: 171-176.
20. Miltiadous, G., M. Elisaf, H. Bairaktari, S. L. Xenophontos, P. Manoli, and M. A. Cariolou. 2001. Characterization and geographic distribution of the low density lipoprotein receptor (LDLR) gene mutations in northwestern Greece. Hum. Mutat. 5: 432-433.
21. Tsimikas, S., C. Bergmark, R. W. Beyer, R. Patel, J. Pattison, E. Miller, J. Juliano, and J. L. Witztum. 2003. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J. Am. Coll. Cardiol. 41: 360-370.
22. Tsimihodimos, V., S. A. Karabina, A. P. Tambaki, E. Bairaktari, G. Miltiadous, J. A. Goudevenos, M. A. Cariolou, M. J. Chapman, A. D. Tselepis, and M. Elisaf. 2002. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J. Lipid Res. 43: 256-263.
23. Liapikos, T. A., S. Antonopoulou, S. P. Karabina, D. C. Tsoukatos, C. A. Demopoulos, and A. D. Tselepis. 1994. Platelet-activating factor formation during oxidative modification of low-density lipoprotein when PAF-acetylhydrolase has been inactivated. Biochim. Biophys. Acta. 1212: 353-360.
24. Holvoet, P., D. Collen, and F. Van de Werf. 1999. Malondialdehyde- modified LDL as a marker of acute coronary syndromes. J. Am. Med. Assoc. 281: 1718-1721.
25. Holvoet, P., J. Vanhaecke, S. Janssens, F. Van de Werf, and D. Collen. 1998. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 8: 1487-1494.
26. Itabe, H., H. Yamamoto, T. Imanaka, K. Shimamura, H. Uchiyama, J. Kimura, T. Sanaka, Y. Hata, and T. Takano. 1996. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J. Lipid Res. 37: 45-53.
27. Holvoet, P., J. M. Stassen, J. Van Cleemput, D. Collen, and J. Vanhaecke. 1998. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 18: 100-107.
28. Van Tits, L. J., T. M. van Himbergen, H. L. Lemmers, J. de Graaf, and A. F. Stalenhoef. 2006. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 185: 307-312.
29. Ehara, S., M. Ueda, T. Naruko, K. Haze, A. Itoh, M. Otsuka, R. Komatsu, T. Matsuo, H. Itabe, T. Takano, et al. 2001. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 103: 1955-1960.
30. Erkkila, A. T., O. Narvanen, S. Lehto, M. I. Uusitupa and S. Ylä-Herttuala. 2000. Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20: 204-209.
31. Hulthe, J., O. Wiklund, E. Hurt-Camejo, and G. Bondjers. 2001. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2). Arterioscler. Thromb. Vasc. Biol. 21: 269-274.
32. Hulthe, J., J. Wikstrand, A. Lidell, I. Wendelhag, G. K. Hansson, and O. Wiklund. 1998. Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 18: 1203-1211.
33. Wu, R., Y. H. Huang, L. S. Elinder, and J. Frostegard. 1998. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 18: 626-630.
34. Hulthe, J., L. Bokemark, and B. Fagerberg. 2001. Antibodies to oxidised LDL in relation to intima-media-thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler. Thromb. Vasc. Biol. 21: 101-107.